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Abstract
Background: Equitable access to essential medicines is a major challenge for policy-makers world-wide, including
Central and Eastern European countries. Member States of the European Union situated in Central and Eastern
Europe have publicly funded pharmaceutical reimbursement systems that should promote accessibility and
affordability of, at least essential medicines. However, there is no knowledge whether socioeconomic inequalities
exist in these countries. Against this backdrop, this study analyses whether socioeconomic determinants influence
the use of prescribed and non-prescribed medicines in eight Central and Eastern European countries (Bulgaria,
Czech Republic, Hungary, Latvia, Poland, Romania, Slovenia, Slovakia). Further, the study discusses observed
(in)equalities in medicine use in the context of the pharmaceutical policy framework and the implementation in
these countries.
Methods: The study is based on cross-sectional data from the first wave of the European Health Interview Survey
(2007–2009). Multivariate logistic regression analyses were carried out to determine the association between
socioeconomic status (measured by employment status, education, income; controlled for age, gender, health
status) and medicine use (prescribed and non-prescribed medicines). This was supplemented by a pharmaceutical
policy analysis based on indicators in four policy dimensions (sustainable funding, affordability, availability and
accessibility, and rational selection and use of medicines).
Results: Overall, the analysis showed a gradient favouring individuals from higher socioeconomic groups in the
consumption of non-prescribed medicines in the eight surveyed countries, and for prescribed medicines in three
countries (Latvia, Poland, Romania). The pharmaceutical systems in the eight countries were, to varying degrees,
characterized by a lack of (public) funding, thus resulting in high and growing shares of private financing (including
co-payments for prescribed medicines), inefficiencies in the selection of medicines into reimbursement and
limitations in medicines availability.
Conclusion: Pharmaceutical policies aiming at reducing inequalities in medicine use require not only a
consideration of the role of co-payments and other private expenditure but also adequate investment in medicines
and transparent and clear processes regarding the inclusion of medicines into reimbursement.
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Background
Ensuring equitable access to essential medicines is a
major challenge for policy-makers. Essential medicines
are those that satisfy the priority health care needs of
the population and should be selected with due regard
to disease prevalence, evidence on efficacy and safety,
and comparative cost effectiveness. Essential medicines
are intended to be available within the context of func-
tioning health systems at all times, in adequate amounts,
in the appropriate dosage forms, with assured quality,
and at a price that the individual and the community
can afford [1]. Countries have the responsibility to provide
access to essential medicines while the implementation of
the concept of essential medicines is intended to be flex-
ible and adaptable to country specific situations [2].
The World Health Organization (WHO) has been pro-
moting the concept of universal health coverage, arguing
that timely access to health services, including medica-
tion, requires a well-functioning health financing system
[3]. Related to pharmaceuticals, this means that, inde-
pendently from the ownership of the suppliers (private
or public suppliers and dispensaries), those medicines
considered as essential in the national context are, at
least partially, funded by the state, through a social
health insurance system or a national health service.
Such reimbursement systems are in place in all Member
States of the European Union (EU) where funding and re-
imbursement of medicines remains a national competence
even if other areas (marketing authorization) have been
harmonized [4]. This is also the case of the Central and
Eastern European countries (CEECs) that are members of
the EU. As of 2015, this is a total of eleven countries:
Czech Republic, Estonia, Hungary, Latvia, Lithuania,
Poland, Slovenia and Slovakia (acceding to the EU in
2004); Bulgaria and Romania (joining the EU in 2007);
and Croatia which has been an EU Member State since
mid-2013.
From the 1990s, the CEECs have changed from highly
centralised and hospital-centred Semaskho systems to-
wards social insurance systems with varying degrees of
state centeredness and liberal market elements [5, 6]. In
terms of pharmaceutical policies, the CEECs departed
from the former principle of free medication for the en-
tire population, starting to differentiate between medi-
cines that should either be fully or partially reimbursed
by the health system and introducing co-payment
schemes for out-patient medicines [7–10].
In the new millennium, all these countries had positive
lists, i.e. lists of medicines that may be prescribed at the
expense of a third party payer (corresponding to the es-
sential medicines lists concept). However, there are indi-
cations that the lists of (co-)funded medicines in the
CEECs were smaller compared to those in the Western,
Northern and Southern EU Member States [9, 10].
Further, medicines included in the positive lists were not
necessarily 100 % funded since medicines whose thera-
peutic benefit was assessed to be lower were funded par-
tially, with the remainder to be paid by out-patients in
out-patient care [8–10]. In order to ensure financial sus-
tainability for medicines, the CEECs implemented, to a
greater or lesser extent, several of the policy options
available: They applied price regulation for medicines, at
least for those (partially) funded by the state at ex-
factory price (manufacturer price) as well as at wholesale
and retail price level (regulating the maximum allowed
profits for distributors and dispensaries) [8–10]. In
addition, lower priced generics were more widely used
in the CEECs compared to other EU Member States: this
might be attributable to a traditionally strong role of
local generic industry, but also to demand-side measures
such as encouraging doctors to prescribe by Inter-
national Non-Proprietary Name (INN) and allowing
pharmacists to substitute prescribed brands by generics
(generic substitution) [11, 12].
Still, investment in health care, including medicines, is
known to be lower in the Central and Eastern European
region, and several CEECs have been struggling with lim-
ited health budgets, making cost-containment a major
policy concern [6, 7, 13]. Consequently, out-of-pocket-
payments, including informal payments [14–17], consider-
ably increased. Respective austerity measures shifted the
financial burden from the state to private households, with
a potential risk that vulnerable population groups refrain
from using health care services, including getting prescrip-
tions filled and purchasing non-prescribed Over-the-
Counter (OTC) medicines [18].
At the same time, limited evidence is available regard-
ing inequalities in medicine use. To our best knowledge,
the socioeconomic determinants of medicine use in the
CEECs have not yet been explored in detail. Exceptions
include Geckova et al. [19], studying socioeconomic dif-
ferences in health, including the use of prescribed and
non-prescribed medicines, of adolescents in Slovakia in
1998, or Gorecka et al. [20] analysing as to whether a so-
cioeconomic gradient existed in the use of (prescribed)
cardiovascular medicines at district level in the Czech
Republic for the years 1997-2000. Though not studying
socioeconomic (in)equalities, the study by Baji et al. [21]
is also relevant in this context: Concerns for socioeco-
nomic inequalities were raised following the increase in
out-of-pocket payments, including co-payments after the
2007 health care reform in Hungary.
Against this background, our study aims to analyse
whether socioeconomic determinants influence medicine
use, i.e. both use of prescribed medicines and non-
prescribed medicines, in eight CEECs (Bulgaria, Czech
Republic, Hungary, Latvia, Poland, Romania, Slovenia,
Slovakia). Based on these findings, we discuss to what
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extent observed inequalities can potentially be explained
by current pharmaceutical policies (or a lack of respect-
ive policies).
This article is thus first to study inequalities in medi-
cine use in CEECs. To this end, we first present a brief
review of the literature on inequalities in health care
and, more specifically, medicine use, and, introduce our
analytical framework. We perform a quantitative analysis
of (in)equalities in medicine use based on household sur-
vey data from the first wave of the European Health
Interview Survey (EHIS). The findings are interpreted in
a policy analysis that follows the developed framework
and uses information and research on national pharma-
ceutical systems.
Addressing inequalities in medicine use
Following the international literature, equitable access to
and equitable use of health care is generally defined as
access to and use of health care that is determined by
health care need rather than any other criteria such as
socioeconomic and demographic factors (e.g. income,
education, sex or age) or the macro level institutional
factors (e.g. health insurance coverage or co-payments).
For medicines, this would require that health care need
and no other potential factor determines access to and
use of medicines. The empirical and policy oriented lit-
erature dealing with (in)equalities in health care revolves
around three major issues: measuring the extent of the
inequalities, identifying the factors that determine in-
equalities and addressing measures that help reduce
existing inequalities.
Over the past two decades, there has been a vastly
growing literature attempting to measure the existence
and the extent of socioeconomic inequalities. This first
stream of the literature is widely covering developing as
well as developed countries (e.g. [22–24]) and has fo-
cused on access to general practitioners (GPs) or special-
ists [25], on access to specific treatments [26], but less
on access to hospital care. Existing studies on inequal-
ities in medicine consumption focus on single countries
[27] or even regions within countries [28], on specific
medicines [29] or specific groups of the population [30],
while there is very little cross-country evidence on socio-
economic inequalities in medicines consumption.
The second stream of the literature goes beyond meas-
uring (in)equalities and applies different frameworks to
disentangle the factors that determine (in)equalities in
access to and use of health care. Much of this work
builds on Andersen’s behavioural model [31], i.e. his
seminal work on the predictive factors for the use of
medical care. While different extensions and adaptations
of the original model exist, the approach primarily differ-
entiates between predisposing factors (including demo-
graphic factors such as age and gender, socioeconomic
factors but also health beliefs or cultural norms), enab-
ling factors (including the financial situation of the user,
the means of transportation but also health care system
conditions) and the need factor (differentiating between
perceived need and evaluated need). Health policies (and
pharmaceutical policies) largely fall into the category of
contextual enabling factors. In a 2012 review of the ap-
plication of Andersen’s model in the 1998-2011 period
[32], 328 articles have been identified, with more than
half referring to the 1995 model [33]. None of the arti-
cles identified in this systematic review has dealt with
the use of medicines. There are, however, studies on
medicine use explicitly or implicitly referring to the
ideas of the Andersen model (e.g., [34]).
Another approach to disentangling the factors that de-
termine unequal access to health care services starts
from a taxonomic definition of the 5As: availability, ac-
cessibility, accommodation, affordability and acceptabil-
ity [35]. For medicines, this approach has been adapted
to include availability, accessibility, acceptability and af-
fordability, with emphasizing quality as a factor relevant
in all the four dimensions [36]. In a more recent adapta-
tion for access to health technologies including medi-
cines, for poor populations, availability and affordability
have been complemented with architecture and adoption
[37]. Bigdeli et al. [38], in an attempt to grasp the com-
plexity of barriers to accessing medicines and to more
explicitly address the actors involved, differentiate be-
tween the demand side level of individuals, households
and communities, health service delivery as the supply
side perspective, health sector governance and the na-
tional and international context beyond the health sector.
This latter approach puts more emphasis on the health
policy perspective. In addition to identifying socioeco-
nomic inequalities in access to and use of health care
and in addition to the aforementioned approaches to
disentangle the factors that determine existing inequal-
ities, the third stream of the literature on inequalities in
health care use deals with the impact of policies on ac-
cess to and use of medicines or on improving access to
health care in general or medicines more specifically. Ex-
amples for this body of work are Gemmill et al. [39] ana-
lysing the impact of prescription medicines charges on
efficiency and equity or Leopold et al. studying the im-
pact of the economic recession on pharmaceutical con-
sumption in eight European countries [40] and the
impact of the policy policies on the use of antipsychotic
medicines for Finland and Portugal [41]. In general, the
more policy oriented literature is broad and often aimed
at very specific health policy concerns. But often it lacks
a coherent framework for analysis. For our study, we fol-
low a WHO approach for collective action towards
equitable access to essential medicines [42], differentiat-
ing between four key actions: rational selection and use
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of essential medicines, affordable prices, sustainable fi-
nancing, and reliable supply systems.
With a view to the aim of this study, discussing the
impact of pharmaceutical policies on (in)equalities in the
use of medicines, and in combining the above cited lit-
erature, we use four key dimensions for the analysis: (1)
sustainable funding, (2) affordability, (3) rational selec-
tion and use of medicines and (4) availability and acces-
sibility. As depicted in Table 1, the first two dimensions
are dealing with financing, (1) on the macro level, (2) on
the micro level, the other two dimension are related to




We draw on cross-sectional data from the first wave of
the European Health Interview Survey (EHIS), collected
between 2006 and 2009 in 19 EU Member States [43].
This study focuses on CEECs. Countries in this region,
due to their weaker economic situation compared to
Western European countries, risk substantial socioeco-
nomic inequalities. Eight (Bulgaria, Czech Republic,
Hungary, Latvia, Poland, Romania, Slovenia, Slovakia) of
the ten CEECs that were EU Member States at the time
of the EHIS survey were included in our study (see
Table 2 for an overview of the dataset); Estonia and
Lithuania were excluded due to limited data and non-
inclusion in the EHIS survey, respectively. Generally, the
data focussed on the non-institutionalized population,
but in the Czech Republic also the institutionalized
population (living in nursing homes and convents/mon-
asteries) was included in the survey [44]. Since this,
however, only concerns less than an estimated 0.5 % of
this country’s sample population (Š Daňková 2014, pers.
comm., 6 October), we hardly expect this to affect our
results. Finally, the EHIS dataset covers the population
above age 15, however, we restrict our analysis to adults
(aged 18 and over) as it is assumed that the development
of an individual socioeconomic status may be expected
from around this age onwards.
To determine the association between socioeconomic
status and pharmaceutical consumption, we carried out
multinomial multivariate logistic regression analyses
(Stata 13.1). In these models, the probability was esti-
mated of falling into certain categories compared to the
reference group. To check the statistical significance of
the calculated relative-risk ratios (RRR), z-statistics were
used. Only results with p < 0.05 were considered statisti-
cally significant and thus discussed further. McFadden’s
R2 is reported as measure of model fit.
A detailed description of the variables included in the
regression analysis can be found in Table 3. The
dependent variable is based on the information on the
consumption of non-prescribed medicines (only), con-
sumption of prescribed medicine (only) and consump-
tion of both types of medicines versus no medicine use.
For an unbiased gender comparison, use of female-
specific medicines (contraceptive pills; hormones for
menopause; based on an additional survey question) was
excluded from the analysis. As independent variables of
interest, three socioeconomic indicators were included
[45]. First, employment status was grouped into
employed (reference group), retired, unemployed or dis-
abled and in training or at home. Second, the highest
level of education completed was measured based on the
International Standard Classification of Education
(ISCED) 1997 and distinguishes between ISCED ≤ 2,
ISCED 3-4 and ISCED 5-6. Third, the income level was
based on the range of the monthly net household in-
come against the values of the national deciles’ limits
and categorized into quintiles (reference group: first
quintile). To control for demographic characteristics, we
included age and sex, with the youngest and males as
reference groups. Finally, since a socioeconomic gradient
in health disadvantaging the poor is also well-established
Table 1 Pharmaceutical policies and equitable access to medicines: a framework for analysis
Macro level Micro level
FINANCING Sustainable funding Affordability
Addressing financial issues on macro levels: the availability of funding
for health care in general and the level of pharmaceutical spending
more specifically
Addressing financial issues on micro levels: who pays and how much,
thus the role of public and private payments for pharmaceuticals
Categories of indicators: type of health care system, total health
expenditure, pharmaceutical expenditure
Categories of indicators: private health expenditure, private
pharmaceutical expenditure, co-payments, informal payments,
medicine prices, VAT on medicines, policies addressing the poor
DELIVERY Rational selection and use Availability and accessibility
Addressing delivery on macro levels: which medicines, at least
potentially, are made available, rational prescribing, dispensing and
use of medicines in the health care system
Addressing delivery on micro levels: the issue of supply meeting
demand in terms of volume and reachability given distances and
travel resources
Categories of indicators: INN prescribing, generic market, reference
price system, prescription monitoring, treatment guidelines
Categories of indicators: number of medicines, pharmacy density,
OTC sale
Note: A definition of all the indicators chosen is given in Table 5 which provides a comparative overview for the eight study countries.
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in CEE regions [46], we introduced dummy variables for
chronic conditions (no chronic conditions as reference
group) and self-assessed health (good as reference
group).
An overview of the descriptive information for the in-
dividual countries is given in Table 4.
Pharmaceutical policy analysis
The analysis of pharmaceutical policies as potential co-
determinant of inequalities in medicine use builds on an
analytical framework based on the WHO approach for
collective action [42] (see Addressing inequalities in
medicine use and Table 1). We identified four key
Table 3 Variable definitions
Variable Survey question Subcategories (as used in the analysis) and reference group
Medicine use During the past two weeks, have you used any medicines
(including dietary supplements such as herbal medicines
or vitamins) that were prescribed or recommended for
you by a doctor?




During the past two weeks, have you used any medicines
or dietary supplement or herbal medicines or vitamins
not prescribed or recommended by a doctor?
Employment status How would you define your current labour status? • Employed (working for pay or profit); reference group
• Retired (in retirement or early retirement or has given up business)
• Unemployed or disabled (unemployed; permanently disabled)a
• In training or at home (pupil, student, further training, unpaid
work experience)
Highest education What is the highest education leaving certificate, diploma
or education degree you have obtained? Please include
any vocation training.
• ISCED ≤ 2 (no formal education or below ISCED 1; primary
education; lower secondary education); reference group
• ISCED 3-4 (upper secondary education; post-secondary but
non-tertiary education)
• ISCED 5-6 (first stage of tertiary education; second stage of
tertiary education)
Income quintile Perhaps you can provide the appropriate range [instead
of the household’s total net income per month]. Would
you (please look at this card and) tell me which group
represents your household’s total net monthly income
from all these sources after deductions for income tax,
National Insurance etc. Is it …
• First quintile; reference group
• Second quintile
• Third quintile
• Fourth and fifth quintile






Gender Sex • Male; reference group
• Female
Chronic conditions Do you have any longstanding illness or [longstanding]
health problem? [By longstanding, I mean illnesses or
health problems which have lasted, or are expected to
last, for 6 months or more.]
• No; reference group
• Yes
Self-assessed health How is your health in general? Is it … • Good (very good, good); reference group
• Poor (very bad, bad, fair)
Note: aAs pointed out by an anonymous reviewers, it can be argued that unemployed and permanently disabled people differ in terms of health and medicine
use and should thus be analysed separately. However, as both groups individually make for a small proportion of the sample and thus only very few observations
would be left for the subgroup analyses (in the most extreme case 0 observations and in the majority of cases, less than 20 observations, which, for Eurostat
confidentially reasons would need to be left blank), it was decided to analyse them as one subgroup.
Source: Data provided by Eurostat [80]; presentation by the authors
Table 2 Data sources

















Response rate in % 74 56 81 72 72 89 68 66
Sample size (age 15+) 5,661 1,995 5,051 6,458 35,100 18,172 2,188 4,972
Note: BG Bulgaria, CZ Czech Republic, HU Hungary, LV Latvia, PL Poland, RO Romania, SI Slovenia, SK Slovakia
Source: Eurostat [44]
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Table 4 Descriptive information
BG CZ HU LV PL RO SI SK
n % n % n % n % n % n % n % n %
Medicine use 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
None 2,185 39.9 508 27.2 1,558 31.8 2,161 35.3 7,714 23.1 9,742 55.8 705 34.8 1570 33.1
Non-prescribed 792 14.5 357 19.1 750 15.3 1,308 21.4 7,036 21.1 1,284 7.4 409 20.2 941 19.9
Prescribed 1,393 25.4 529 28.3 1,557 31.8 1,381 22.6 7,022 21.0 5,013 28.7 595 29.3 1,051 22.2
Both 666 12.2 454 24.3 1,031 21.0 1,084 17.7 7,835 23.4 1,351 7.7 318 15.7 1,157 24.4
Missing 439 8.0 18 1.0 3 0.1 180 2.9 3,809 11.4 74 0.4 1 0.0 18 0.4
Employment status 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 86.5 2,028 85.9 4,737 89.9
Employed 2,682 49.0 995 53.3 2,462 50.3 3,324 54.4 15,836 47.4 8,261 47.3 1,005 49.6 2,798 59.1
Retired 1,875 34.2 594 31.8 1,322 27.0 1,551 25.4 9,263 27.7 6,132 35.1 553 27.3 991 20.9
Unemployed, disabled 631 11.5 104 5.6 740 15.1 602 9.9 4,002 12.0 722 4.1 184 9.1 471 9.9
In training, at home 287 5.2 173 9.3 375 7.7 637 10.4 4,315 12.9 2,349 13.0 286 14.1 477 10.1
Missing 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Highest education 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
ISCED ≤ 2 1,830 33.4 292 15.6 1,289 26.3 1,760 28.8 7,741 23.2 6,381 36.5 903 44.5 525 11.1
ISCED 3-4 2,754 50.3 1,370 73.4 2,728 55.7 3,155 51.6 20,257 60.6 9,568 54.8 955 47.1 3,311 69.9
ISCED 5-6 889 16.2 196 10.5 877 17.9 1,196 19.6 5,418 16.2 1,515 8.7 170 8.4 901 19.0
Missing 2 0.0 8 0.4 5 0.1 3 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Income quintile 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
1 1,384 25.3 189 10.1 1,048 21.4 201 3.3 3,530 10.6 9,592 54.9 260 12.8 559 11.8
2 577 10.5 217 11.6 890 18.2 2,101 34.4 5,860 17.5 6,190 35.4 358 17.7 947 20.0
3 787 14.4 383 20.5 1,015 20.7 2,809 45.9 5,915 17.7 595 3.4 281 13.9 1,034 21.8
4–5 2,452 44.8 683 36.6 1,537 31.4 1,003 16.4 10,884 32.6 171 1.0 611 30.1 1,603 33.8
Missing 275 5.0 394 21.1 409 8.3 0 0.0 7,227 21.6 916 5.2 518 25.5 594 12.5
Age 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
18–29 767 14.0 344 18.4 841 17.2 1,328 21.7 6,673 20.0 2,717 15.6 420 20.7 1,121 23.7
30–39 751 13.7 344 18.4 919 18.8 963 15.8 5,261 15.7 2,985 17.1 338 16.7 965 20.4
40–49 894 16.3 243 13.0 756 15.4 984 16.1 5,361 16.0 2,840 16.3 355 17.5 800 16.9
50–59 1,061 19.4 320 17.1 933 19.0 972 15.9 6,804 20.4 3,320 19.0 380 18.7 837 17.7
60–69 948 17.3 326 17.5 732 14.9 882 14.4 4,548 13.6 2,593 14.8 279 13.8 577 12.2
70+ 1,054 19.3 289 15.5 718 14.7 985 16.1 4,769 14.3 3,009 17.2 256 12.6 437 9.2
Missing 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Gender 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.1 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
Male 2,588 47.3 891 47.7 2,225 45.4 2,692 44.1 15,295 45.8 8,202 47.0 948 46.8 2,271 47.9
Female 2,887 52.7 975 52.3 2,674 54.6 3,422 56.0 18,121 54.2 9,262 53.0 1,080 53.3 2,466 52.1
Missing 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0 0 0.0
Chronic conditions 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
No 3,020 55.2 951 51.0 1,430 29.2 3,413 55.8 15,705 47.0 11,143 63.8 1,245 61.4 1,957 41.3
Yes 2,429 44.4 904 48.4 3,467 70.8 2,692 44.0 17,557 52.5 6,206 35.5 779 38.4 2,767 58.4
Missing 26 0.5 11 0.6 2 0.0 9 0.1 154 0.5 115 0.7 4 0.2 13 0.3
Self-assessed health 5,475 100.0 1,866 100.0 4,899 100.0 6,114 100.0 33,416 100.0 17,464 100.0 2,028 100.0 4,737 100.0
Good 3,099 56.6 1,161 62.2 2,529 51.6 2,661 43.5 16,287 48.7 11,252 64.4 1,237 61.0 2,975 62.8
Bad 1,950 35.6 703 37.7 2,369 48.4 3,275 53.6 13,346 39.9 6,204 35.5 789 38.9 1,756 37.1
Missing 426 7.8 2 0.1 1 0.0 178 2.9 3,783 11.3 8 0.0 2 0.1 6 0.1
Source: Data provided by Eurostat [43]; calculation and presentation by the authors
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dimensions for the analysis, (1) sustainable funding, (2)
affordability, (3) rational selection and use of medicines
and (4) availability and accessibility. For each of the
four dimensions, we developed a set of indicators (see
Tables 1 and 5).
To fill these indicators with country specific informa-
tion, we drew on several data sources: Background infor-
mation and data for the policy analysis were taken from
the literature, predominantly grey literature. Search
terms included ‘medicines’, ‘pharmaceuticals’, ‘equity’, ‘ac-
cess’ and the name of the country. We focussed on the
period around the EHIS survey, and three years before,
and also literature with overall relevant information, e.g.
related to the transition process, was included. Country
reports about national pharmaceutical systems were a
key source of information, in particular the PPRI
(Pharmaceutical Pricing and Reimbursement Informa-
tion) Pharma Profiles (available for five of the eight
CEECs), the Health Systems in Transition reports by the
European Observatory on Health Systems and Policies
as well as country reports produced by the Organisation
for Economic Co-operation and Development (OECD)
and by the Austrian Public Health Institute (references
listed below Table 5 and below the additional table [see
Additional file 1]). Since some of the reports did not refer
to the exact years of the survey, unpublished information
from the PPRI network was used as supplementary source
[47, 48]. Health and pharmaceutical expenditure data were
retrieved from the Eurostat database [49].
Based on the information and data collected for the
countries, we produced eight brief country posters [see
Additional file 1]) and an overview table (Table 5). Fol-
lowing methods of policy analysis research [50], we used
the country specific information and data to understand
whether the identified socioeconomic (in)equalities in
medicine use were impacted by the existing implementa-
tion degree of pharmaceutical policies. In the analysis, we
interpreted ‘prescribed medicines’ as medicines funded, at
least partially, by state (independently from their prescrip-
tion status: both prescription-only and non-prescription
medicines), whereas ‘non-prescribed medicines’ were con-
sidered as non-funded self-medication.
Results
As can be seen from the descriptive information for the
individual countries (Table 4), the proportion of people
reporting to take no medicine at all ranged between
23.1 % (Poland) and 39.9 % (Bulgaria) in all countries ex-
cept for Romania, in which 55.8 % reported no medicine
consumption. Romania also holds a special position re-
garding non-prescribed medicine use (7.4 %), which lied
between 14.5 % (Bulgaria) and 21.4 % (Latvia) in the
remaining countries. Prescribed medicines (only) were
taken by around 21.0 % (Poland) and 31.8 % (Hungary)
of the surveyed populations.
Socioeconomic (in)equalities in medicine use
Overall, in the regression analyses we find that whenever
there is a socioeconomic gradient in medicine consump-
tion to be observed in a country, it will in virtually every
case favour the well-off, as shown in Figs. 1 and 2, respect-
ively. The full results including all variables of the country-
specific multinomial logistic regression analyses are
presented in an additional table [see Additional file 2].
For non-prescribed medicine use (versus no medicine
use), individuals with higher education and/or income
had a higher chance of taking such medicines in seven
of the eight CEECs: In Hungary, for instance, individuals
in the highest education group were estimated to be four
times more likely to take non-prescribed medicines
(RRR = 4.32, 95 % CI = 2.98–6.27) while the relative risk
for people in high income households increases by a fac-
tor of 1.66 (95 % CI = 1.20–2.31), respectively, given the
other variables in the model are held constant. In
Poland, on the other hand, the observed gradient was
comparably less pronounced (highest education: RRR =
1.79, 95 % CI = 1.55–2.07; highest income: RRR = 1.38,
95 % CI = 1.20–1.58). Only in Bulgaria, neither education
nor income played any role for non-prescribed medicine
use, but the unemployed and disabled were attributed a
lower consumption likelihood.
For prescribed medicines, in contrast, a statistically sig-
nificant socioeconomic gradient could be identified in
three economies only, i.e. Latvia, Poland, Romania: The
increased likelihood of the highest education groups in
these countries (Latvia: RRR = 2.09, 95 % CI = 1.59–2.73;
Poland: RRR = 1.92, 95 % CI = 1.62–2.27; Romania: RRR =
1.73, 95 % CI = 1.19–2.54) is similar in magnitude,
whereas in terms of the highest income groups, Latvia
showed the most pronounced effect with an RRR close to
2 (RRR = 1.99, 95 % CI = 1.17–3.37).
Regarding the influence of demographic characteristics
on medicine use [see Additional file 2], females were
more likely to take (any) medicines in general, whereas
advanced age was particularly relevant for prescribed
pharmaceutical consumption, which is consistent with
the literature [51]. Such prescribed medicine use was
also highly determined by health characteristics, espe-
cially by longstanding illnesses.
Pharmaceutical policies
Details on the pharmaceutical policies in the CEECs
are provided in Table 5 and an additional table [see
Additional file 1]. Key features are as follows: Health
and pharmaceutical expenditure, primarily funded by
social health insurance contributions, was low com-
pared to the Western European countries, and the
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Table 5 Pharmaceutical policy framework – Indicators for equitable access to essential medicines
Indicator BG CZ HU LV PL RO SI SK
Reference year 2008 2008 2009 2008 2009 2008 2007 2009
Sustainable funding
HC system SHI SHI SHI SHI SHI SHI SHI SHI
TPE in % of THE 33.4 % (0.0 pp) 20.4 % (-4.4 pp) 32.5 % (+1.5 pp) 19.4 % (-2.6 pp) 22.9 % (-4.3 pp) 25.0 % (-3.2 pp) 19.6 % (-1.1 pp) 26.6 % (-3.2 pp)
TPE share
(CEE-10 comparison)
+9.0 pp −4.0 pp +6.7 pp −5.0 pp −1.5 pp +0.6 pp - 6.0 pp +3.2 pp
TPE per capita € 109.9 (+50.3 %) € 205.6 (+17.1 %) € 229.4 (+0.8 %) € 134.3 (+66.6 %) € 134.5 (+11.7 %) € 92.2 (+59.1 %) € 264.0 (+12.0 %) € 283.5 (+56.6 %)
TPE/capita
(CEE-10 comparison)
−39.1 % +14.0 % +35.3 % −25.6 % −16.5 % −48.9 % +56.9 % +47.0 %
Affordability
Private HE/THE 41.8 % (+6.5 %) 17.5 % (+37.5 %) 34.3 % (+13.5 %) 37.4 % (-12.7 %) 28.2 % (-6.0 %) 18.0 % (-6.2 %) 28.1 % (+4.6 %) 34.3 % (+8.3 %)
Private HE/THE
(CEE-10 compar.)
+13.6 pp −10.8 pp +4.7 pp +9.2 pp - 0.1 pp −10.3 pp −2.2 pp +4.0 pp
Private PE/TPE 81.7 % (+4.8 %) 38.4 % (+56.9 %) 51.6 % (37.7 %) 62.2 % (-9.4 %) 61.4 % (0 %) 55.0 % (+4.8 %) 40.1 % (+2.9 %) 30.2 % (+11.3 %)
Private PE/TPE
(CEE-10 comp.)
+27.8 pp −15.5 pp −2.9 pp +8.3 pp +7.8 pp +1.2 pp −13.7 pp −25.2 pp
Informal pays Yes, extensive Yes Yes Yes, extensive Yes Yes, large scale No Yes
Medicine prices n.a. € 5.09 (-71.4 %) € 6.91 (-61.2 %) € 4.23 (-76.2 %) € 4.54 (-74.5 %) n.a. € 12.34 (-30.8 %) n.a.
Co-pays (out-patient) No PF PF PF No PF PF for some indications No PF No PF PF
%: 0 %, >25
%, >50 %
No fixed R rates %: 0 %, 10 %, 30 %;
25 %, 45 %, 75 %
%: 0 %, 10 %, 25 %,
50 %, 25 %
%: 0 %, 30 %, 50 % %: 0 %, 10 %, 50 % %: 0 %, 25 %,
75 %
%: no fixed R rates
No D No D No D No D No D No D No D No D
Changes in co-pays No Yes Yes, increase No, but planned (90 %
R rate to be abolished)
No since mid-
1990-ties
No No Yes, decrease in PF
in 10/2006
Co-pay exempt. None None Yes Yes Yes Yes, see comment Yes Yes
De-listings No, see comment Not known Yes, see comment See comment Yes See comment No No major delisting
Co-pays (in-patient) No co-payment No co-payment No co-payment No co-payment No co-payment No co-payment No co-payment No co-payment
VAT on medicines 20 % (20 %) 9 % (19 %) 5 % (20 %) 5 % (18 %), planned
increase from 1/2009
7 % (22) 9 % (19 %) 8.5 % (20 %) 10 % (19 %)
OTC market 22 % 26.8 % 15.8 % n.a. 25.8 % 22.4 % 6.7 % 25.8 %
Availability and accessibility
No. of medicines 5,8302006 7,8802006 5,525 2006 n.a. (8,0892005) 6,7112007 2,7912006 19,693 November 2006
4,4812006 4,1302006 3,1442006 5,7142007 4,2752006 ≈4,0002007 n.a. 19,320November 2006
1,598 6,9882006 2,8862006 2,3372007 2,7492006 5,7912007 2,6602006 17,804November 2006













Table 5 Pharmaceutical policy framework – Indicators for equitable access to essential medicines (Continued)
Pharmacies 4,299/1,7952006 2,520/4,0962007 ≈2,500/≈4,0002010 899/2,2092007 10,632/3,5852007 5,660/3,7332007 271/7,3842005 1,523/3,528Oct. 2006
OTC sale outside
pharmacies permitted
Yes Yes Yes No No Yes, but pharmacist
must be present
Yes No
Rational selection and use of medicines
INN prescribing Yes, indicative Yes, indicative Yes, indicative Yes, indicative Yes, indicative Yes, indicative Yes, indicative Yes, indicative
Generic substitution No, not allowed Yes, indicative Yes, indicative Yes, obligatory Yes, indicative Yes, indicative Yes, indicative Yes, obligatory
Ref. price syst. Yes, ATC 5 Yes, ATC 4 + 5 Yes, ATC 4 + 5 Yes, ATC 3,4 + 5 Yes, ATC 3,4 + 5 Yes, ATC 5 Yes, ATC 4 Yes, ATC 4 + 5
Generic market See comment 55 %/35 %2005 42 %/26 %2005 No data No data ≈70 %/≈40 %e 70 %/38 %2005 65 %/48 %2005
Prescription
monitoring
Yes, but limited Yes Yes, but limitations
in enforcement






Reference year: data in this table refer to the year of the household survey unless indicated differently
HC system: indicates the type of health care system: Semaskho system, social health insurance (SHI) or National Health Service (NHS)
TPE in % of THE: Total pharmaceutical expenditure (TPE) in % of total health expenditure (THE) in the year of the survey; in brackets: change in the share of TPE in % of THE in percentage points compared to
3 years earlier
TPE share (CEE-10 comparison): Difference of the share of TPE in % of THE in the surveyed country in 2008 compared to CEE-10 average (Bulgaria, Czech Republic, Estonia, Latvia, Lithuania, Hungary, Poland, Romania,
Slovenia, Slovakia) in 2008, expressed in percentage points
TPE per capita: Total pharmaceutical expenditure (TPE) per capita in the year of the survey, in Euro; in brackets: change in TPE per capita compared to 3 years earlier, expressed in per cent)
TPE/capita (CEE-10 comparison): Difference of the TPE per capita in the surveyed country in 2008 compared to CEE-10 average in 2008, expressed in per cent
Private HE/THE: Private health expenditure (HE) in % of total health expenditure (THE) in the year of the survey (unless BG – 2007 data); in brackets: change in the share of private HE in % of THE in per cent compared
to 3 years earlier
Private HE/THE (CEE-10 compar.): Difference of the share of private HE in % of THE in the surveyed country in 2008 compared to CEE-10 average in 2008 (unless BG – 2007 data), expressed in percentage points
Private PE/TPE: Private pharmaceutical expenditure (PE) in % of total pharmaceutical expenditure (TPE) in the year of the survey; in brackets: change in the share of private PE in % of TPE in per cent compared to
3 years earlier
Private PE/TPE (CEE-10 comp.): Difference of the share of private PE in % of TPE in the surveyed country in 2008 compared to CEE-10 average in 2008, expressed in percentage points
Informal pays: Indications of informal payments in health care
Medicine prices: Average pharmacy retail price in € per pack in the total out-patient market in 2006; differences in % to average of EU-15
Co-pays (out-patient): Co-payments for medicines in the out-patient sector: PF = prescription fee, % = percentage co-payment rates (for reimbursable medicines different co-payment rates in per cent of the price of
product apply, usually linked to the severity of the disease and therapeutic benefit of the medicine), D = deductible (upfront initial out-of-pocket payment up to a fixed amount for a service or over a
defined period of time; then the rest of the cost is covered by a public party payer). Percentage co-payments due to the reference price system (see below indicator ‘Ref. pricing syst.’) are not considered.
Changes in co-pays: Changes in co-payments in the years before the survey
Co-pay exempt.: Mechanisms for vulnerable groups (e.g. exemptions, reductions) from co-payments in the out-patient sector
De-listings: Exclusion of medicines from reimbursement in the years before the survey
Co-pays (in-patient): Co-payments for medicines in the in-patient sector
VAT on medicines: Value-added tax (VAT) rate on medicines; in bracket: standard VAT rate
OTC market: Relevance of the Over-the-Counter (OTC) market expressed by the share of sales in total non-prescription market as per cent of total pharmaceutical market sales in the years of the EHIS
survey (at consumer price level, unless indicated differently)
No. of medicines: Number of medicines authorized, medicines on the market, and prescription-only medicines. Counted incl. different pharmaceutical forms and dosages, excl. different pack sizes unless
indicated differently
Pharmacies: Number of community pharmacies, and inhabitants per pharmacy served
OTC sale outside pharmacies permitted: Information as to whether the sale of Over-the-Counter (OTC) medicines was permitted outside pharmacies, or not
INN prescribing: Information as to whether prescribing by International Non-Proprietary Name (INN) was permitted, and if yes, whether the policy was voluntary (indicative) or mandatory for the prescriber
Generic substitution: Information as to whether the practice of substituting a medicine, whether marketed under a trade name or generic name (branded or unbranded generic), with a less expensive medicine (e.g.
branded or unbranded generic), often containing the same active ingredient, was permitted, and if yes, whether the policy was voluntary (indicative) or mandatory for the pharmacist
Ref. price syst.: Information as to whether a reference price system was in place, i.e. a reimbursement policy, in which identical or similar medicines are clustered – the public payer reimburses a defined maximum
amount (reference price) for all medicines of the cluster, and patients have to co-pay the remainder up to the pharmacy retail price gross), and its clustering: ATC-5: clustering of same active ingredients or groups of
active ingredients, ATC-4: clustering of medicines of the same therapeutic group, clustering of medicines of the same pharmacological subgroup













Prescription monitoring: Information as to whether prescription monitoring was performed
Abbreviations: ATC Anatomical Therapeutic Chemical classification system, D deductible, HE health expenditure, OTC Over-the-Counter medicines, pp percentage points, PE pharmaceutical expenditure, PF prescription
fee, R reimbursement, THE total health expenditure, TPE total pharmaceutical expenditure, VAT value-added tax
Notes:
BG:
Private HE / THE and Private HE / THE (CEE-10 compar.): no data for private health expenditure in 2008 available; 2007 data used instead: change indicated for the years 2004-2007
Changes in co-pays: Increase of percentage co-payments for some medicines, treating Parkinson, osteoporosis, Glaucoma, etc. took place after the EHIS survey, in 2010
De-listings: No de-listings reported but constant increase of medicines included in the positive list during 2007
No. of medicines: Different data sources and counting methods for medicines authorized and on the market compared to prescription-only medicines. The latter were counted per brand name, excl. different pharmaceutical forms,
dosages and pack sizes. Counted according to that method, the number of the medicines on the market were 4,299, thus resulting in a share of prescription-only medicines of the medicines on the market of around 37 %.
Pharmacies: High regional disparities in the density of pharmacies, concentration in larger cities
Generic market: No data on generic market shares available. 74 % of the medicines on the market are generics.
CZ:
Co-pays (out-patient): Percentage co-payment rates result from application of the reference price system
Changes in co-pays: In 2008 (year of the survey), a prescription fee was introduced, as well as further co-payments in health care (not medicines related) such as a co-payment for visit to a doctor
Pharmacies: High regional disparities in the density of pharmacies, concentration in larger cities
HU:
Co-pays (out-patient): Percentage co-payment rates of 0, 10 and 30 % for out-patient medicines for specific indications, and of 25, 45 and 75 % for all other reimbursable medicines in the out-patient sector
Co-pay exempt.: Exemptions from co-payment for socially disadvantaged persons. 100 % reimbursement for patients with long-term illness, however, the prescription fee had also to be paid by them
De-listings: A few de-listings, and changes in reimbursement categories (pharmaceutical groups were granted a lower percentage reimbursement rate) at large scale since 2006/2007
No. of medicines: Counted per brand name, excl. different pharmaceutical forms, dosages and pack sizes
Pharmacies: In addition to pharmacies, around 370 doctors are also allowed to dispense prescription-only medicines
Prescription monitoring: Limitations particularly related to off-patent medicines: guidelines for cost-effective prescribing are frequently not followed, no audit or feed-back of the social health insurance on generic prescribing
by doctors
LV:
De-listings: De-listings were not explicitly reported but took place most probably: since 2005 major changes in the reimbursement list were reported, the principle of a limited number of medicines in the positive list
was in place, and regular reimbursement reviews were performed. Medicines were included in the positive list for a period of 2 years, then the marketing authorization holder had to apply for re-inclusion.
No. of medicines: Number of medicines authorized not included since medicines are only counted per trade name
Pharmacies: Including 100 branch pharmacies, availability of pharmacies varied between towns and rural areas
PL:
OTC market: At manufacturer price level; refers to self-medication market
No. of medicines: Data on number of prescription-only medicines includes hospital-only medicines. In 2009, 3,380 medicines (counted including different pharmaceutical forms, dosages and pack sizes) were on the
reimbursement list. Data on authorized medicines have to be interpreted with caution due to a different counting method: counted including different dosages, pharmaceutical forms and pack sizes.
Pharmacies: High regional disparities in the density of pharmacies, concentration in larger cities
RO:
Co-pay exempt.: Exemptions from co-payments are made for children, students and pregnant women as well as war veterans and disabled people on low income
De-listings: Quarterly updates of the reimbursement lists; no confirmed information of major de-listings (however number of medicines on the reimbursement list is, in general, rather low)
No. of medicines: 1,247 of the 5,791 prescription-only medicines were hospital-only medicines
Pharmacies: High regional disparities in the density of pharmacies, concentration in larger cities
Generic market: Estimate for the year 2007
SI:
Co-pays (out-patient): Co-payments covered by voluntary insurance that around 90 % of the population concluded
Co-pay exempt.: Exemptions from co-payments for medicines for prevention, for defined social groups (such as people under 18 years) or for the treatment of specific diseases (e.g. HIV/AIDS, diabetes)
De-listings: No major wave of de-listings reported; on the contrary, some new medicines could be included in the positive lists following changes in medicine prices due to change in pricing methodology
OTC market: At wholesale price level, refers to self-medication market
No. of medicines: Counted including different dosages, pharmaceutical forms and pack sizes
Pharmacies: Some OTC medicines were ‘pharmacy-only’, whereas others were permitted to be sold in ‘specialised stores’ outside pharmacies
SK:
No. of medicines: Counted including different pharmaceutical forms, dosages and pack sizes; homeopathic medicines excluded
Sources: Indicator 2: [7, 10, 81–89]; Indicators 3-10: [49]; Indicator 11: [14–16, 63, 83, 86, 88–100]; Indicator 12: [68]; Indicators 13-16, 18, 20, 22-24, 26, 27: [9, 63, 101–111]; Indicator 17: [112–117]; Indicator 19: [53–55];













share of health expenditure spent on medicines was
rather high. In 2008, the EU-15 (i.e. 15 countries
from Western, Northern and Southern Europe that
joined the EU before 2004), spent an average of € 424
on medicines, corresponding to around 15.6 % of
total health expenditure, whereas average figures
equalled to € 180 and 24.4 % in the CEE-10 (the eight
surveyed countries plus Estonia and Lithuania) [49, 52].
Within the eight surveyed CEECs, major discrepancies
existed both in terms of the share of health expend-
iture spent on medicines and per capita pharmaceut-
ical expenditure. Pharmaceutical expenditure was
particularly low in Romania and Bulgaria, and also in
Latvia and Poland. High increases in pharmaceutical
expenditure were observed in Latvia (67 % during the
three years before the survey), Romania (59 %) and
Slovakia (57 %).
Private funding of health care, particularly of medi-
cines (on average 54 % in the CEE-10), was high com-
pared to the EU-15 with 38 % [49, 52], and there was
considerable variation between the surveyed CEECs:
Bulgaria had the highest share of private pharmaceutical
spending (82 %), followed by Latvia (62 %) and Poland
(61 %). Apart from Latvia and Poland, the share of pri-
vate pharmaceutical expenditure had grown in the three
years before the EHIS survey, particularly in the Czech
Republic (57 %) and Hungary (38 %). Private pharma-
ceutical expenditure resulted from full out-of-pocket
payments in the case of self-medication (non-prescribed,
non-reimbursable medicines) and from co-payments of
Fig. 1 Socioeconomic determinants of non-prescribed medicine use (versus no medicine use). Note: Graphical illustration of the full results [see
Additional file 2] regarding non-prescribed medicine use for socioeconomic indicators; RRR =multivariate relative risk ratio, CI = 95 % confidence
interval, grey line: not significant, red line: *** = significant at 0.01 %, ** = significant at 0.1 %, * = significant at 5 %. Results based on less than 20
observations: tightly dashed line and exact numbers omitted; results based on 20-49 observations: widely dashed line and exact numbers in
italics. Source: Data provided by Eurostat [43]; calculation and presentation by the authors
Vogler et al. International Journal for Equity in Health  (2015) 14:124 Page 11 of 19
reimbursable medicines (i.e. medicines whose cost were,
at least, partially covered by public payers). Market
shares for non-prescription and self-medication medi-
cines were higher than in Western European countries
[53–55]. Whereas no co-payments were applied in the
in-patient sector in the CEECs, they were charged for
out-patient medicines: Some countries had prescription
fees, and all CEECs applied co-payments as percentage
of the price for those medicines that displayed a lower
therapeutic value. De-listings (i.e. exclusion of medicines
from reimbursement) were reported for some CEECs,
and they contributed to increased private pharmaceutical
expenditure.
The number of authorized medicines and of medicines
on the market was usually lower in the CEECs than in
the other European countries (for data on Europe see
[9]). Except for Slovenia, pharmacy density was higher in
the surveyed CEECs than in Western European coun-
tries (an average of 3,360 and 5,780 inhabitants per phar-
macy in the EU-10 and the EU-15 respectively in 2005,
[9]). But major intra-country discrepancies resulting in
low accessibility to pharmacies in the rural areas existed
in some CEECs (Bulgaria, Czech Republic, Poland,
Romania). The sale of (specific) OTC medicines outside
pharmacies was permitted in all surveyed CEECs but
Latvia, Poland and Slovakia.
Pricing and reimbursement is a national competence
in the EU Member States under the condition that over-
all procedural provisions, as laid down in the EU Trans-
parency Directive [56] such as deadlines for pricing and
reimbursement decisions, for instance, are complied with.
The CEECs adapted their pricing and reimbursement
Fig. 2 Socioeconomic determinants of prescribed medicine use (versus no medicine use). Note: Graphical illustration of the full results [see
Additional file 2] regarding prescribed medicine use for socioeconomic indicators; RRR =multivariate relative risk ratio, CI = 95 % confidence
interval, grey line: not significant, red line: *** = significant at 0.01 %, ** = significant at 0.1 %, * = significant at 5 %. Results based on less than 20
observations: tightly dashed line and exact numbers omitted; results based on 20-49 observations: widely dashed line and exact numbers in
italics. Source: Data provided by Eurostat [43]; calculation and presentation by the authors
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systems to the ‘acquis communitaire’ before acceding to
the EU in 2004 and 2007, respectively [57]. Some CEECs
(Czech Republic, Slovenia, Slovakia) undertook additional
changes in the years before the EHIS survey, to further
strengthen their institutional framework and/or to react to
new challenges, such as high-cost medicines [see country
profiles in Additional file 1]. At the time of the survey,
Poland was fundamentally changing its pharmaceutical
pricing and reimbursement system following a European
Commission’s infringement procedure related to the EU
Transparency Directive that also addressed long decision
times. Related to demand-side measures, measures to en-
courage rational prescribing and use of medicines, includ-
ing a promotion of generics’ uptake, were in place in the
CEECs, but limited enforcement was reported.
Overall, the literature review identified several key
challenges and shortcomings in the pharmaceutical sys-
tems of the investigated CEECs: In all countries but
Slovenia high co-payments and out-of-pocket payments
as well a limited enforcement of measures to promote a
more rational prescribing and use of medicines (includ-
ing encouraging generics uptake) were an issue. Under-
funding of the pharmaceutical system was reported from
Bulgaria, the Czech Republic, Latvia and Romania, and
informal payments on a major scale were identified in
Bulgaria, Hungary, Latvia, Poland, and Romania. Bulgaria,
Poland and Romania were criticized for inefficiencies in
procedures and policy coordination. Slovenia was the only
country out of the eight CEECs for which the above-
mentioned deficits were not reported. However, Slovenia
was struggling with limited availability of medicines, and
so did Bulgaria, Latvia and Romania.
Discussion
According to the analysis of EHIS survey data higher so-
cioeconomic groups were found to have a comparably
higher likelihood to use non-prescribed medicines in all
eight surveyed CEECs and to use prescribed medicines
in three countries (Latvia, Poland, and Romania). Our
findings are partly in line with the very few studies on
this issue: Geckova et al. [19] found a pro-rich socioeco-
nomic gradient in non-prescribed medicine use and a
pro-poor gradient in prescribed medicine use of adoles-
cents in Slovakia in 1998. Gorecka et al. [20] identified
geographic variation in the use of cardiovascular medi-
cines level in the Czech Republic for the years 1997-
2000 and attributed this to socioeconomic factors.
The eight CEECs have a social health insurance system
in place that should, in principle, ensure coverage of the
entire population and would allow linking health related
social exclusion to the social policy context which is
considered important [57]. The identified socioeconomic
inequalities, particularly to prescribed medicine use,
might result from deficits in the social insurance systems
(issues of non-participation were reported for some
CEECs (e.g. Bulgaria: [58]) and from lack of or ineffi-
ciencies in specific pharmaceutical policies. In the fol-
lowing, we explore potential factors that are able to
contribute to the socioeconomic (in)equalities observed.
Sustainable funding
A major prerequisite for equitable access to medicines is
sustainable funding [38, 42]. The comparably low
pharmaceutical expenditure in Romania (€ 92 per capita)
and Bulgaria (€ 110 per capita), but also Latvia and
Poland (around € 135 per capita) points to possible
underfunding. Insufficient investment in the field of
medicines could be one explanation for the socioeco-
nomic gradient in prescribed medicine use observed in
Latvia, Poland and Romania. The more than 50 % in-
crease in per capita pharmaceutical expenditure in
Latvia, Romania, Slovakia and Bulgaria in the three years
before the survey could be interpreted as countries’ ef-
forts to invest into medicines, but it might also be an in-
dicator that the countries spent more than their
economic situation allowed and thus negatively im-
pacted sustainability.
Affordability
Apart from Slovakia, all above mentioned countries had
shares of private pharmaceutical expenditure of more
than 55 % (Bulgaria as high as 82 %). The high patients’
contributions in Latvia, Romania and Poland are likely a
major reason for the non-use of non-prescribed, pri-
vately funded medicines, but they might also explain the
socioeconomic gradient in prescribed medicine use ob-
served in these countries since patients were frequently
required to co-pay for out-patient prescribed medicines.
Further co-payments in health care could be additional
barriers for patients with a lower socioeconomic back-
ground to visit a doctor and get a prescription: In the
CEECs co-payments for attending a physician were, gener-
ally, in place, supplemented by ‘under-the-table payments’.
Overall economic developments are key drivers for
policy-makers to curb publicly financed expenditure,
even more with the global financial crisis. The Czech Re-
public, for instance, introduced co-payments to doctors’
visits and significantly increased the value-added tax
(VAT) on medicines in 2008, and the share of the private
pharmaceutical spending had grown by 57 % within
three years. This could explain the socioeconomic gradi-
ent in non-prescribed use, and it might also lead to so-
cioeconomic inequalities in prescribed medicine use
though this was not confirmed by the EHIS results on
the Czech Republic.
Within the CEECs Latvia, Hungary and Romania were
particularly impacted by the global financial crisis [59].
Latvia responded through several cost-containment
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measures [60, 61]. This probably aggravated existing so-
cioeconomic inequalities whose existence in health care
(not medicines) had been identified as extensive in
Latvia, also in comparison to the other Baltic countries
[62]. In Romania, accessibility to prescribed, reimburs-
able medicines was strongly limited at the time of the
survey due to high co-payments for out-patient medi-
cines, and particularly due to the existence of pharma-
ceutical budgets for pharmacies: Once a monthly
financial threshold had been reached a pharmacy was no
longer permitted to fill prescriptions [63]. Thus, patients
could not access prescribed medication unless they were
willing, and able, to pay for it out-of-pocket. In 2007,
after years of galloping growth rates in pharmaceutical
expenditure, Hungary launched a reform to drastically
curb public pharmaceutical expenditure. As a result, the
share of private pharmaceutical expenditure (52 %) was
rather high at the time of the survey (2009), and it had
considerably grown (by 38 %) within the previous three
years. This may cause concerns about limited affordabil-
ity for lower socioeconomic groups [28]. Despite this
austere cost-containment strategy no socioeconomic
gradient in prescribed medicine use was found. A pos-
sible explanation is provided by a study on Hungary [64]
according to which affordability of medicines was not
negatively impacted by the cost-containment measures.
It was argued that the policies were designed in a way to
particularly target market participants (industry, distri-
bution actors) rather than private households. Medicine
prices were drastically cut, for instance, but this resulted
in lower (percentage) co-payments for the patients.
Medicine prices should be affordable for those who
pay for them – public payers and private households.
There is lack of knowledge about prices of OTC medi-
cines in general [65], and these prices have not been sur-
veyed in the CEECs either. The socioeconomic gradient
in non-prescribed medicine use that was found in all
eight CEECs potentially implies that patients with a
lower socioeconomic background considered medicines,
which had to be paid out-of-pocket, as not affordable. In
this context, attention should be paid to the value-added
tax (VAT) on medicines. In many low- and middle-
income countries world-wide, taxes and duties account
for a considerable share of the medicine prices, thus
contributing to increasing medicine prices up to an un-
affordable level for the majority of the population [66].
In the CEECs, the only relevant tax related to the price
of a medicine is the value-added tax. In the CEECs the
VAT rates on medicines (amounting to 10 % or less)
tended to be lower than the standard VAT rates [9, 67]
and lower compared to the other EU countries. None-
theless, they had risen in some countries (Czech Repub-
lic, Poland, Romania, Slovenia) from usually 5 % in 2004
[7] to their current rates of between 7.5 and 10 % since
an increase in VAT rates was a common cost-
containment policy [60]. While it might not appear high,
it might still result in a medicine price of non-funded
medicines that lower socioeconomic groups were not
able, or not willing, to afford.
Little can be said about whether medicine prices were
affordable for public payers in the CEECs given the lack
of price studies in this region. One study [68] on 23
European countries that also included six CEECs showed
that the pharmacy retail price (i.e. price at pharmacy) in
the CEECs, except for Slovenia, was considerably lower
than in the other European countries. However, unpub-
lished analyses from the Pharma Price Information ser-
vice of the Austrian Public Health Institute [69]
indicated that at the time of the EHIS survey prices for
specific new, high-cost medicines (e.g. cancer medicines,
orphan medicines) were comparably high. These medi-
cines were typically fully funded by public payers, and
this ensured access to higher-priced medicines for the
patients. This might explain why a socioeconomic gradi-
ent for prescribed medicine use was found in only three
of the eight CEECs included in our study.
Availability and accessibility
Limited medicine availability was an issue in the CEECs.
However, availability deficits were apparently not linked
to the socioeconomic background of the patients, but
targeted the whole population, as in the case of Slovenia
and Latvia with a low number of medicines authorized
and/or on the market. These countries are considered as
‘small markets’ that might not be sufficiently attractive
for the pharmaceutical industry to be supplied [70]. Lim-
ited availability also resulted from medicine shortages,
i.e. that medicines were not supplied in sufficient quan-
tity to pharmacies and hospitals. This was reported to be
a major problem in Romania [71]. Furthermore, we
found indications of regional inequalities: Despite the
generally high pharmacy density in the CEECs (except
for Slovenia), major intra-country discrepancies existed
in some CEECs (Bulgaria, Czech Republic, Poland,
Romania) and resulted in low accessibility to pharmacies
in the rural areas. Regarding the regional variation of
OTC retailers, based on the experience from Western
European countries about a clustering of these dispens-
aries in towns with already good accessibility [65], it can
be assumed that the easier access to OTC medication
was likely to primarily serve well-off people in the urban
areas who were willing and able to pay for these non-
funded medicines. This would contribute to regional
inequalities within countries, but depending on the re-
gional distribution of socioeconomic groups can also
contribute to the socioeconomic gradient identified in
this paper.
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Rational selection and use of medicines
A major need for improving the pricing and reimburse-
ment procedure was reported from Bulgaria and
Romania whose processes were considered unclear and
intransparent. The design of a pricing and reimburse-
ment system is not simply a technical issue but it can
considerably impact accessibility and affordability: Un-
clear and intransparent processes encourage corruption
and an irrational selection of medicines into reimburse-
ment, and this, eventually, can limit sustainable public
funding. Cumbersome long processes, as observed for
Poland, might result in delays in access to needed medi-
cines for patients.
The CEECs have been criticized for not paying enough
attention to promoting a rational use of medicines [57]
that aims to ensure that patients receive the appropriate
medicine at the right dose and at the time they require.
The instruments to encourage rational prescribing
existed in the CEECs but were apparently not fully
enforced. Knowing this, however, we cannot draw con-
clusions as to whether the medicine use reported in the
EHIS survey was appropriate, or not.
Given the limits in funding by both public payers and
private households, promoting the uptake of generics is
considered as a recommended policy option [72]. The
CEECs already had comparably high generic market
shares, since local generic industries played a strong role
historically, even before the transition process [73], and
the use of prescribed generics was promoted by tools
such as INN prescribing and generic substitution. Still,
high reluctance versus the quality of generics was re-
ported [12]. Thus, awareness-raising campaigns to in-
form about generics could be a policy to reduce in the
observed socioeconomic gradient in non-prescribed use,
by motivating people to use lower priced generics.
Reducing socioeconomic inequalities through
pharmaceutical policies?
Summarizing, the policy analysis identified some factors
that help explain the observed socioeconomic gradient
in non-prescribed medicine use in the eight CEECs and
in prescribed medicine use in three of them. These in-
clude a high and increasing share of private funding such
as co-payments for prescribed out-patient medicines and
co-payments beyond medicines (e.g. for attending doctors
to get a prescription), limited investment in medicines,
and long and intransparent processes regarding the inclu-
sion of medicines into reimbursement. Further deficits
such as limited availability of medicines, irrational
prescribing and regional variation in the accessibility of
pharmacies and OTC retailers are additional factors limit-
ing an equitable access but it could not be determined
whether, or not, lower socioeconomic groups are particu-
larly affected. The analysis of the pharmaceutical policies
in Latvia, Poland and Romania provides an indications
that actually these policies contribute to the observed so-
cioeconomic inequalities in prescribed medicine use in
these countries. While the three countries cannot be seen
as a very homogenous cluster in terms of pharmaceutical
policies, they share an accumulation of policies that do
not adequately address inequalities in medicines use. Simi-
larly, for Bulgaria, the policy framework observed would
suggest a socioeconomic gradient in prescribed medicine
use. This, however, was not confirmed based on the EHIS
data. Also, it might have been possible that cost-
containment policies would have had a negative impact
on equitable access to medicines in the Czech Republic
and in Hungary. In this respect, note that the only two
other studies [19, 20] on socioeconomic determinants in
medicine use in CEECs, focussing on adolescents in
Slovakia and on cardiovascular medicines in Czech Re-
gions did identify a socioeconomic gradient. Though
pharmaceutical policies were apparently successful in re-
ducing socioeconomic inequalities in medicine use in
some CEECs, further factors were likely to have an impact.
These might be factors at the individual level of the pa-
tients (e.g. adherence to medicines) as well as overall polit-
ical and economic factors, such as the stability of a health
care system, patients’ trust into it and the impact of the
transition processes as observed in the CEECs in the
1990-ties. Finally, the non-existence of a socioeconomic
gradient in medicine use can still imply any under-use,
over-use or misuse of medicines in general, and overall
limited availability and accessibility of medicines for the
patients of that country.
Limitations
This study does not come without limitations. First, the
quantitative analysis is based on self-reported informa-
tion and hence comes with a risk of measurement er-
rors. However, at the individual country level, where
data was collected, several quality control steps were
taken [74] and data comparability was also ensured by
Eurostat, based e.g. on a standard questionnaire, concep-
tual guidelines and rationales as well as a standard transla-
tion protocol [75, 76]. Data was collected either via a
stand-alone survey or as part of another (health or non-
health) survey (i.e. national health interview survey, labour
force survey, other household survey) based on face-to-
face interviews, telephone interviews, self-administered
questionnaires (or a combination of these means) [77].
Consistency and integrity checks on the national EHIS
data were carried out by Eurostat, and quality reports
were also disseminated [74]. Also, household surveys are
an acknowledged standard tool in pharmaceutical con-
sumption research according to the WHO [78]. Second,
the EHIS household surveys goes beyond the regulatory
definition of medicines in national legislations since
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‘dietary supplements such as herbal medicines or vitamins’
were part of a question on medicine use (Table 3). To find
out if this influences our results, sensitivity analyses were
carried out excluding both the use of ‘vitamins, minerals
or tonics’ or/and ‘some other type or medicine or supple-
ment’, respectively. While the socioeconomic gradient was
generally found to be less pronounced but still statistically
significant in these sensitivity analyses, the qualitative con-
clusions regarding the socioeconomic gradient identified
in the main analysis remained the same. Third, inter-
viewees were asked about their use of ‘medicines pre-
scribed or recommended by a doctor’ and ‘medicines not
prescribed or recommended by a doctor’ (Table 3). Since
we had no information about medicines recommended
but not prescribed, we interpreted these two categories of
‘prescribed’ and ‘non-prescribed use’. We based this ap-
proach on the assumption that doctors tend to believe
that patients expect a prescription [79]. Fourth, the ana-
lysis refers to different time periods between 2007 and
2009. We investigated the pharmaceutical policy frame-
work at the time of the EHIS survey at national level, but
for comparing national data (e.g. expenditure) versus a
European or CEE average a specific year (2008) was taken
as reference. This was, in some cases, not the year of the
survey. Also, the survey comes with different national
sample sizes. This seems especially relevant for Poland,
where the analysis is based on a comparatively large study
population, and thus even small differences between so-
cioeconomic groups may become statistically significant.
Finally, non-use of medicines can have numerous causes.
We explored whether the pharmaceutical policy frame-
work impacts, positively or negatively, on socioeconomic
(in)equalities. However, as the wealth of literature on ad-
herence rightly points out, there are several other reasons
for not using medicines or stopping prescribed medication
prematurely. To identify the relative importance of the
various factors as co-determinants of the use or non-use
of medicines, in-depth investigation for single countries is
needed in future research.
Conclusion
Our study confirmed a socioeconomic gradient in medi-
cine use in Central and Eastern Europe: Socioeconomic
inequalities in non-prescribed medicine use were found
in all eight surveyed CEECs, whereas for prescribed
medicines this was only the case in three countries
(Latvia, Poland, and Romania). The latter could be an in-
dication that pharmaceutical policies, which typically
refer to publicly (co-)funded medicines, had been able to
successfully address inequalities in the other CEECs. In-
creasing public funding for medicines, and reductions in
and exemptions from co-payments for vulnerable groups
are likely appropriate strategies to ensure more equitable
access to medicines. In addition, an increased generics
uptake, a more rational selection of medicines into reim-
bursement and more rational prescribing can contribute
to raise resources for public spending.
Our study confirms that pharmaceutical policies, and
their implementation and enforcement, are important
tools to address socioeconomic inequalities. As a more
general conclusion, with improved knowledge about the
extent and the character of socioeconomic inequalities
in medicine consumption in CEECs as well as in other
parts of the world, pharmaceutical policies could be used
more effectively as a major tool to improve access to
medicines across entire populations.
This study refers to the years 2007-2009. Meanwhile,
the CEEC region has been severely affected by the global
financial crisis. The economic situation has led to in-
creasing poverty and growing financial pressure for large
parts of the populations, which, not least, can lead to
changes in medicine consumption. Further, public bud-
gets came under increasing pressure, a pressure that also
tightens financial scope for pharmaceutical policies. For
future research, it is suggested to follow up this study by
analysing pharmaceutical policies in the CEECs during
the crisis and exploring their impact on medicine use.
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